Cameron Health Commences Clinical Trial of the Minimally Invasive Totally Subcutaneous Implantable Defibrillator for Treatment of Sudden Cardiac Arrest

Cameron Health, Inc. announces the first CE trial implants in Europe and New Zealand for Cameron Health’s Subcutaneous Implantable Defibrillator (S-ICD®) System.

The minimally invasive S-ICD System is prescribed for use in patients at risk of sudden cardiac arrest (SCA). The system is unique in that the implantation of the system is entirely subcutaneous; no leads are in or on the heart. Additionally, there is no imaging equipment required for placement of the S-ICD System, as all of the components may be positioned using anatomical landmarks.

Acute improvement in left ventricular function and mitral insufficiency has been reported using a biventricular pacemaker. In this article, we report on Cambodia’s first biventricular pacemaker implantation.

Case Report

The patient was a 45-year-old Cambodian male with one month of progressive dyspnea on exertion. He presented to Centre de Cardiologie de Phnom Penh in New York Heart Association Class IV congestive heart failure and cardiac cachexia on February 13, 2008. Initial physical examination revealed a blood pressure of 97/63, heart rate of 80 bpm, and elevated jugular venous pressure. Cardiac examination revealed a regular sinus rhythm, enlarged and laterally displaced cardiac point of maximal impulse, S4, S1, S2, and S3 gallop. A mitral systolic murmur with intensity of 4/6 was noted. Pulmonary examination revealed bilateral pulmonary rales. He also had hepatomegaly and 4+ peripheral edema.

Sheffield Hospitals and Trust are bringing translational research to clinical practice and using new technology to help staff deliver high quality care, no matter who responds to a patient in cardiac arrest. This article will discuss key research articles and how they have been brought to clinical practice in the Sheffield system. This article will also discuss the choice of a new defibrillator throughout the trust and how its adoption was guided by recent research in resuscitation.

An unexplained loss of consciousness can be a very scary experience, especially when its causes cannot be explained or diagnosed. Syncope affects a million and a half Americans each year, and unfortunately, more than 40% of cases are misdiagnosed or go undiagnosed. Therefore, the STARS (Syncope Trust and Reflex Anoxic Seizures) organization was created in order to offer patients, families, and medical staff with support and information.

STARS, a national non-profit organization, is committed to improving the quality of life for individuals and their families coping with blackouts, unexplained losses of consciousness, and syncope. This can include syncope disorders, reflex anoxic seizures (RAS), and postural tachycardia syndrome (POTS). Their main focus is educating and supporting sufferers, their families, the medical community and general public by offering a support system where they can obtain knowledge and understanding of these conditions.

Background